McDonald's CEO, Chris Kempczinski, said that the $5 deal is "driving other purchases," raising the average check "north of ...

Anthos Therapeutics is a clinical-stage biopharmaceutical company developing abelacimab, a potential first-in-class monoclonal antibody targeting the FXI inhibition pathwayAbelacimab is currently in P ...

Fast-food giant reports weaker profit; international markets show progress.

McDonald's Corp. is pushing ahead with ambitious expansion plans for 2025, announcing approximately 2,200 new restaurant ...

McDonald’s E. coli incident last year stopped customers in their tracks, leading to the chain’s worst quarterly sales result ...

A near-term technical floor is getting priced in at the 50-day Exponential Moving Average (EMA) near 43,750. Both bulls and bears appear to have run out of gas for the time being, but the Dow Jones is ...

Recently, the firm has been leaning into its scale-driven cost advantage to emphasize its value offerings amid a challenging consumption spending environment. We view this strategy as prudent.

McDonald’s on Monday reported disappointing quarterly revenue, dragged down by weaker-than-expected sales at its U.S.

McDonald's executives told analysts during an earnings call Monday that the company faced a financial blow from the deadly E. coli outbreak that occurred last year.

The burger giant saw customer visits weaken following an E.coli outbreak that started on October 22 and forced them to temporarily suspend sales.

We have data showing the most in-demand jobs so far in 2025 and how much they pay. Also in Money today: farm shop owner Stephen Fuller explains what it's really like being a butcher - from salary to ...